From struggling with sickle cell disease to climbing mountains - a firsthand account of how gene therapy has been life changing
Jimi Olaghere describes how his life has changed after participating in a clinical trial for the CRISPR based gene therapy for sickle cell disease that is now called CASGEVY. He describes what it was like receiving the treatment, and discusses the need for more awareness and access in the sickle cell community worldwide for this type of treatment.
--------
11:07
Bonum Therapeutics aims to lower the toxicity of medicines such as cytokines by regulating them via a unique sensor domain that is designed to activate a therapeutic at its target
Founder & CEO John Mulligan describes how he and his team sold an asset using the same science to Roche in 2022 for $250 million when they were Good Therapeutics, and how the follow-on company Bonum aims to test this approach more broadly. He describes how it works, and discusses the initial programs they have chosen, with a LAG3-IL2 being the most advanced.
--------
18:30
Alta Partners' Managing Director Bob More shares his take on biotech and his philosophy of investing in people - from the Timmerman Report 10th Anniversary Celebration in Seattle
He discusses the current downturn, they key of being focused, and his preference of investing in people first. Plus, comments on portfolio companies eGenesis and Vir Biotechnology.
--------
6:16
Congratulations to Luke Timmerman on 10 years of Timmerman Report. We salute you!
Celebrating with the Seattle (and beyond) biotech community.
--------
5:38
Tour of Scotland: Glasgow based EnteroBiotix is developing microbiome based treatments using a 'full ecosystem' of strains you would expect to see in a healthy microbiome
CEO Jame Mcllroy describes the scientific platform and how it contrasts to other microbiome approaches. A trial in IBS is scheduled to read out immanently.
España